Amarin Corp Plcuk (AMRN) Goodwill & Intangibles (2012 - 2026)
Amarin Corp Plcuk (AMRN) reported Goodwill & Intangibles of $32.1 million for Q1 2026, up 104.86% year-over-year from $15.7 million in Q1 2025, and up 140.04% quarter-over-quarter from $13.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Goodwill & Intangibles (2012 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 15 years of Goodwill & Intangibles data on file, last reported at $32.1 million in Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $32.1 million, up 104.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.1 million (up 104.86% YoY), and the FY2025 annual result was $13.4 million, down 59.73% from the prior year.
- Goodwill & Intangibles advanced to $32.1 million in Q1 2026 per AMRN's latest filing, from $13.4 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $33.2 million in Q4 2023 and troughed at $13.4 million in Q4 2025.
- A 5-year average of $25.7 million and a median of $32.1 million in 2022 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2025 and 2026: Goodwill & Intangibles slumped 59.73% in 2025, then jumped 104.86% in 2026.
- A 5-year view of Goodwill & Intangibles shows it stood at $21.8 million in 2022, then surged by 52.38% to $33.2 million in 2023, then changed by 0.0% to $33.2 million in 2024, then tumbled by 59.73% to $13.4 million in 2025, then jumped by 140.04% to $32.1 million in 2026.
- Business Quant data shows AMRN's Goodwill & Intangibles at $32.1 million in Q1 2026, $13.4 million in Q4 2025, and $14.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.08 Mn |
| Dec 31, 2025 | 13.37 Mn |
| Sep 30, 2025 | 14.07 Mn |
| Jun 30, 2025 | 14.93 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | 33.19 Mn |
| Sep 30, 2024 | 33.19 Mn |
| Jun 30, 2024 | 33.19 Mn |
| Mar 31, 2024 | 18.58 Mn |
| Dec 31, 2023 | 33.19 Mn |
| Sep 30, 2023 | 32.86 Mn |
| Jun 30, 2023 | 20.38 Mn |
| Mar 31, 2023 | 32.86 Mn |
| Dec 31, 2022 | 21.78 Mn |
| Sep 30, 2022 | 32.08 Mn |
| Jun 30, 2022 | 32.08 Mn |
| Mar 31, 2022 | 22.91 Mn |
| Dec 31, 2021 | 32.08 Mn |
| Sep 30, 2021 | 32.08 Mn |
| Jun 30, 2021 | 32.08 Mn |